Trial Profile
A randomized, double-blind, phase III study comparing biosimilar rituximab (RTXM83) plus CHOP chemotherapy versus a reference rituximab plus CHOP (R-CHOP) in patients with Diffuse Large B-Cell Lymphoma (DLBCL) given as first line
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Aug 2022
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Prednisone; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors mAbxience
- 01 Mar 2018 New source identified and integrated (Iranian Registry of Clinical Trials; IRCT2014121612398N5).
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 19 Sep 2017 Status changed from active, no longer recruiting to completed.